IPP Bureau
AstraZeneca-Sputnik V combination demonstrates high immunogenicity profile: RDIF
By IPP Bureau - August 20, 2021
Preliminary data from the first 20 participants in Azerbaijan show antibodies to the SARS-CoV-2 virus spike protein (S-protein) elicited in 100% of cases
Zydus Cadila receives Emergency Use Authorisation for 3-dose ZyCoV-D vaccine
By IPP Bureau - August 20, 2021
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
Second-Gen mRNA COVID-19 vaccine candidate CV2CoV show positive signs in preclinical study
By IPP Bureau - August 19, 2021
The preclinical study provides evidence for strongly improved immune responses with second-generation mRNA backbone jointly developed by CureVac and GSK compared to CureVac’s first-generation mRNA backbone
Agilent Technologies Foundation partners with five hospitals for Covid-19 research
By IPP Bureau - August 19, 2021
Agilent Technologies Inc. announced the contribution of Agilent AriaMx Real-Time qPCR instruments to five research hospitals in India to support their COVID-19 initiatives and help them serve the community at large
Semglee approval to provide huge opportunities in the US insulin biosimilar market
By IPP Bureau - August 19, 2021
FDA approval of the first interchangeable biosimilar insulin will drive the US Insulin biosimilar market, says Kuick Research.
Sai Life Sciences opens discovery biology facility in Hyderabad
By IPP Bureau - August 19, 2021
The company's discovery services support a wide range of global innovator companies from start-ups to large pharma companies, across a diverse set of therapeutic areas including oncology, CNS, antivirals, and inflammation among others
MedAlliance enrols patients for ED study with Sirolimus Drug-Eluting Balloon
By IPP Bureau - August 19, 2021
It is estimated that 300 million men worldwide were affected by ED in 2020, a figure projected to increase to 322 million by 2025. Nearly 30% of these were aged between 40 and 70
FDA grants breakthrough device designation to Impella ECP, the world’s smallest heart pump
By IPP Bureau - August 19, 2021
It measures 9 French (3 millimetres) in diameter upon insertion and removal from the body. While in the heart, it expands to support the heart’s pumping function, providing flow greater than 3.5 L/min
FDA grants Emergency Use Authorization for next-generation Covid-19 assays
By IPP Bureau - August 19, 2021
Thermo Fisher’s kits leverage an updated design from the original TaqPath assays, targeting eight different genes across three regions of the virus that causes Covid-19
Finding a cure for HIV
By IPP Bureau - August 19, 2021
The group, known as the HIV Obstruction by Programmed Epigenetics (HOPE) Collaboratory, will be led by researchers at Gladstone Institutes, Scripps Research Florida, and Weill Cornell Medicine. Their approach, which aims to both silence and permanently remove HIV from the body, takes advantage of knowledge about how other viruses have become naturally inactivated over time.
Ind-Ra predicts growth in US sales for Indian pharma from H2FY22
By IPP Bureau - August 18, 2021
Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
ANG Lifesciences acquires Ind-Swift formulation facilities for Rs 60 cr
By IPP Bureau - August 18, 2021
The company expects a potential sales turnover of Rs.350-500 crores at 100 % capacity utilization
Swastika Investmart and Medcords Healthcare join hands to finance medical stores
By IPP Bureau - August 18, 2021
Through the Sehat Sathi App business can access unsecured business loans at low interest
Wellness Forever Medicare expands its presence as it opens 15 new stores
By IPP Bureau - August 18, 2021
It strengthens its presence to over 250 stores
EpiEndo Pharma secures EUR 20 Million Series A funding for Macrolide
By IPP Bureau - August 18, 2021
The financing secures funds to advance the clinical development of EpiEndo’s lead compound EP395, which entered phase I clinical trials in April, through Phase IIa, targeting COPD as a primary indication
